Drug Trial Radar · NCT02229851
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.
Last checked: Nov 20, 2026Latest source record: Nov 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Oct 31, 2014
Primary completion
Apr 21, 2017
Study completion May 7, 2018
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 23 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.
Conditions
- Growth Hormone Disorder
- Adult Growth Hormone Deficiency
Interventions
somapacitanDrug
Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
somatropinDrug
Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
placeboDrug
Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Truncal Fat Percentage (Week 34)Time frame: Week -3, week 34
Locations
117 sites in 19 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Los Angeles, California
Novo Nordisk Investigational Site
Aurora, Colorado
Novo Nordisk Investigational Site
Atlanta, Georgia
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Baltimore, Maryland
Novo Nordisk Investigational Site
Boston, Massachusetts
Novo Nordisk Investigational Site
East Lansing, Michigan
Novo Nordisk Investigational Site
St Louis, Missouri
Novo Nordisk Investigational Site
Omaha, Nebraska
Novo Nordisk Investigational Site
Omaha, Nebraska
Novo Nordisk Investigational Site
Las Vegas, Nevada
Novo Nordisk Investigational Site
Reno, Nevada
Novo Nordisk Investigational Site
New York, New York
Novo Nordisk Investigational Site
Cleveland, Ohio
Novo Nordisk Investigational Site
Portland, Oregon
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania
Novo Nordisk Investigational Site
Philadelphia, Pennsylvania
Novo Nordisk Investigational Site
Pittsburgh, Pennsylvania
Novo Nordisk Investigational Site
El Paso, Texas
Novo Nordisk Investigational Site
Houston, Texas
Novo Nordisk Investigational Site
Plano, Texas
Novo Nordisk Investigational Site
San Antonio, Texas
Novo Nordisk Investigational Site
Shavano Park, Texas
Novo Nordisk Investigational Site
Salt Lake City, Utah
Novo Nordisk Investigational Site
Federal Way, Washington
Novo Nordisk Investigational Site
Seattle, Washington
Novo Nordisk Investigational Site
Blacktown, New South Wales, Australia
Novo Nordisk Investigational Site
Coffs Harbour, New South Wales, Australia
Novo Nordisk Investigational Site
Darlinghurst, New South Wales, Australia
Novo Nordisk Investigational Site
St Leonards, New South Wales, Australia
Novo Nordisk Investigational Site
Woolloongabba, Queensland, Australia
Novo Nordisk Investigational Site
Box Hill, Victoria, Australia
Novo Nordisk Investigational Site
Parkville, Victoria, Australia
Novo Nordisk Investigational Site
Nedlands, Western Australia, Australia
Novo Nordisk Investigational Site
São Paulo, São Paulo, Brazil
Novo Nordisk Investigational Site
Aachen, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.